Harvard Management Company’s Dianthus Therapeutics DNTH Stock Holding History

Harvard Management Company’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,788	Closed	-$252K	–	23
2023 Q2	$252K	Hold	20,788	–	–	0.02%	33
2023 Q1	$264K	Hold	20,788	–	–	0.03%	48
2022 Q4	$131K	Hold	20,788	–	–	0.02%	46
2022 Q3	$469K	Hold	20,788	–	–	0.06%	46
2022 Q2	$399K	Hold	20,788	–	–	0.05%	45
2022 Q1	$965K	Hold	20,788	–	–	0.1%	42
2021 Q4	$1.47M	Hold	20,788	–	–	0.14%	41
2021 Q3	$2.42M	Hold	20,788	–	–	0.14%	35
2021 Q2	$3.25M	Hold	20,788	–	–	0.19%	31
2021 Q1	$3.94M	Hold	20,788	–	–	0.22%	33
2020 Q4	$2.61M	Hold	20,788	–	–	0.14%	26
2020 Q3	$2.26M	Hold	20,788	–	–	0.12%	22
2020 Q2	$2.5M	Hold	20,788	–	–	0.21%	18
2020 Q1	$2.09M	Hold	20,788	–	–	0.33%	16
2019 Q4	$5.04M	Hold	20,788	–	–	0.53%	16
2019 Q3	$3.41M	Hold	20,788	–	–	0.32%	14
2019 Q2	$4.91M	Hold	20,788	–	–	1.21%	13
2019 Q1	$5.48M	Sell	20,788 -4,923	-19%	-$849K	1.39%	10
2018 Q4	$2.35M	Buy	25,711 +4,923	+24%	+$671K	0.49%	14
2018 Q3	$4M	Hold	20,788	–	–	1.02%	17
2018 Q2	$4.49M	Buy	+20,788	New	+$4.69M	1.06%	14

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Harvard Management Company's DNTH Position: Q3 2023 in Review

Harvard Management Company sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 20,788 shares — an estimated $252K sold.

Harvard Management Company first reported a position in DNTH in Q2 2018 and held it in 21 quarters. The position peaked at $5.48M in Q1 2019. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

Harvard Management Company reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 20,788 Dianthus Therapeutics shares in Q3 2023, an estimated $252K.
Harvard Management Company first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 21 quarters.
Harvard Management Company's Dianthus Therapeutics position peaked at $5.48M in Q1 2019.
30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.